Cancer clinical trials in the region Grand Est

194 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Early Access Lymphoma

Accès précoce post-AMM – COLUMVI (Glofitamab)

B cell lymphoma Large B cell lymphoma 2 3 or more

Systemic Treatment-Naive

Hoffmann-La Roche

Early Access Lung cancer

Accès précoce pré-AMM– IMFINZI (Durvalumab)

SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy

AstraZeneca

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT (Amivantamab)

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive

Janssen

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT (Amivantamab)

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy

Systemic Treatment-Naive

Janssen

Early Access Lymphoma

Accès précoce post-AMM – COLUMVI (Glofitamab)

B cell lymphoma Large B cell lymphoma 1

Systemic Treatment-Naive

Hoffmann-La Roche

Phase 3 Kidney cancer #NCT07227402

[LITESPARK-033] Étude clinique du belzutifan et du zanzalintinib chez les personnes atteintes d'un cancer du rein récurrent après un traitement adjuvant (MK-6482-033)

Clear cell carcinoma Locally Advanced Metastatic None Immunotherapy Systemic Treatment-Naive

La Polyclinique Gentilly - Nancy - Elsan (Nancy)

Merck Sharp & Dohme LLC

Phase 3 Lung cancer #NCT06635824 #2024-512998-27-00

[ABBIL1TY NSCLC-06] Essai visant à évaluer la supériorité de l'association ACASUNLIMAB et PEMBROLIZUMAB par rapport au DOCETAXEL, traitement de référence dans le cancer du poumon non à petites cellules

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 Immunotherapy Chemotherapy

ALK BRAF EGFR KRAS G12C KRAS non G12C MET RET ROS-1 Systemic Treatment-Naive Car-T

Ghrmsa - Hôpital Emile Muller (Mulhouse)

Genmab

Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00

MOSUNETUZUMAB - LENALIDOMIDE par rapport aux choix de l'investigateur chez les patients atteints de lymphome de la zone marginale en rechute ou réfractaire

B cell lymphoma Marginal zone lymphoma None > 60 ml/min 50-60 ml/min 30-50 ml/min 1 2 3 or more Targeted therapy Monoclonal antibodies

Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant

CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy)

The Lymphoma Academic Research Organisation (LYSARC)

Phase 3 Lymphoma #NCT04224493 #2024-510690-16-00

[SYMPHONY-1] Étude du TAZEMETOSTAT par rapport au placebo lorsqu'il est administré en association avec le LENALIDOMIDE et le RITUXIMAB chez des participants atteints de lymphome folliculaire récidivant/réfractaire

B cell lymphoma Follicular lymphoma None > 60 ml/min 50-60 ml/min 30-50 ml/min 1 2 3 or more Chemotherapy Monoclonal antibodies Radiotherapy

Systemic Treatment-Naive

CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Ghrmsa - Hôpital Emile Muller (Mulhouse)

Epizyme, Inc. (Ipsen)

Phase 3 Lung cancer #NCT05899608 #2024-513087-26-00

[HARMONi-3] Étude clinique de l'IVONESCIMAB pour le traitement de première intention des patients atteints d'un CPNPC épidermoïde métastatique

NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Metastatic None Systemic Treatment-Naive

ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg)

Summit Therapeutics